cagrilintide and semaglutide 2.4 mg Efficacy safety of co-administered once-weekly 2·4 with once-weekly 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial Safety, tolerability, pharmacokinetics, and pharmacodynamics

After 1 year without the medication, those in the obesity group regained an average of 0.5% of body weight, and those in the diabetes group lost an additional 1.3% of body weight on average

Mechanism of Action : Both formulations work by mimicking GLP-1 to regulate blood sugar and reduce appetite

If fatigue persists, assess total calorie intake and consider increasing protein to 1.2g per kilogram body weight to support lean mass preservation during rapid weight loss

However, some patients might experience mild side effects during their weight loss journey, such as dizziness, nausea, vomiting, upset stomach, diarrhea, tiredness and constipation